Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek [Yahoo! Finance]
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Scotiabank from $426.00 to $430.00. They now have a "sector perform" rating on the stock.
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at Truist Financial Co. from $550.00 to $460.00. They now have a "buy" rating on the stock.
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at JPMorgan Chase & Co. from $503.00 to $500.00. They now have an "overweight" rating on the stock.